Olympiad Research LP Makes New Investment in LifeStance Health Group, Inc. $LFST

Olympiad Research LP purchased a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,207 shares of the company’s stock, valued at approximately $198,000.

Several other institutional investors have also recently added to or reduced their stakes in LFST. Park Edge Advisors LLC acquired a new position in shares of LifeStance Health Group in the second quarter worth $52,000. Xponance Inc. purchased a new stake in LifeStance Health Group during the 1st quarter worth about $69,000. Public Employees Retirement System of Ohio acquired a new stake in LifeStance Health Group in the 2nd quarter valued at about $70,000. Blair William & Co. IL purchased a new position in shares of LifeStance Health Group in the 2nd quarter valued at about $70,000. Finally, Kapitalo Investimentos Ltda purchased a new position in LifeStance Health Group in the first quarter worth approximately $87,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 8,407,643 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the sale, the director owned 33,524,715 shares of the company’s stock, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the transaction, the insider directly owned 33,524,715 shares of the company’s stock, valued at approximately $169,970,305.05. This trade represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 20,407,643 shares of company stock worth $103,466,750 over the last 90 days. Company insiders own 3.20% of the company’s stock.

LifeStance Health Group Trading Up 1.4%

NASDAQ:LFST opened at $6.40 on Friday. LifeStance Health Group, Inc. has a 12-month low of $3.74 and a 12-month high of $8.30. The company has a current ratio of 1.58, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The stock’s 50 day simple moving average is $5.40 and its 200-day simple moving average is $5.27. The firm has a market cap of $2.49 billion, a P/E ratio of -213.33 and a beta of 1.15.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. The company had revenue of $363.81 million for the quarter, compared to analysts’ expectations of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. LifeStance Health Group’s revenue was up 16.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.02) EPS. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on LFST shares. BTIG Research increased their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Wall Street Zen cut LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. UBS Group upped their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, BMO Capital Markets assumed coverage on shares of LifeStance Health Group in a research report on Thursday. They set an “outperform” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.